-- Scott Roberts
FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is
the first drug to be approved by the U.S. Food and Drug
Administration to treat benign kidney tumors among people with a
rare genetic condition called tuberous sclerosis complex (TSC), the
agency said in a news release.
TSC causes non-cancerous tumors of the brain, kidney and other
organs, the FDA said. The disease affects up to 40,000 people in
the United States, and as many as 80 percent develop kidney
Afinitor helps suppress these tumors by blocking a protein
that's essential for their development and growth, the FDA
The drug's safety and effectiveness were clinically evaluated
among 118 people with TSC. The most common side effects were
inflamed or sore mouth, nausea and vomiting, acne, eczema, cough,
headache, diarrhea, abdominal pain, joint pain and swelling of the
legs or arms. Some 15 percent of females who took Afinitor missed
at least one menstrual period.
Afinitor was first approved by the FDA in 2009 to treat kidney
tumors that weren't treated successfully with other drugs.
Afinitor is produced by Novartis, based in East Hanover,
To learn more about this drug, visit the U.S.
National Cancer Institute.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.